Acute liver failure; Clinical features and management

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 9, 1999, Pages 977-984

  Bernal, William ^a   Wendon, Julia ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acetaminophen; Acute liver failure; Intensive care; Transplantation

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACETYLCYSTEINE; AMIODARONE; ANTIINFECTIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CARBON TETRACHLORIDE; COCAINE; CYPROTERONE; DANAZOL; DICLOFENAC; DOPAMINE; ERYTHROMYCIN; FINASTERIDE; FUSIDATE SODIUM; HALOTHANE; HYDROXYCHLOROQUINE; LAMOTRIGINE; MANNITOL; PARACETAMOL; PAROXETINE; PHENYTOIN; SULFONAMIDE; TUBERCULOSTATIC AGENT; VIGABATRIN;

ARTIFICIAL VENTILATION; BRAIN DISEASE; BRAIN EDEMA; CLINICAL FEATURE; EARLY DIAGNOSIS; HEMODIALYSIS; HEMODYNAMICS; HEMOFILTRATION; HEMOPERFUSION; HUMAN; INFECTION; INTENSIVE CARE; KIDNEY DISEASE; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG DISEASE; MORTALITY; NONHUMAN; PATIENT CARE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SURVIVAL; VIRUS HEPATITIS;

EID: 0032726477     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199909000-00005     Document Type: Review

References (58)

1. Trey C, Davidson C. The management of fulminant hepatic failure. In: Progress in Liver Failure. Popper H, Schaffner F (eds). New York: Grune and Stratton; 1970. pp. 292-298.
2. O'Grady J, Schalm S, Williams R. Acute liver failure; redefining the syndromes. Lancet 1993; 342:273-275. Most recent classification of acute liver failure.
3. Williams R. Classification and clinical syndromes of acute liver failure. In: Acute Liver Failure. Lee W, Williams R (eds). Cambridge: Cambridge University Press; 1997. pp. 1-9.
4. Acharya S, Dasarathy S, Kumar T, Sushma S, Prasanna K, Tandon A, et al. Fulminant hepatitis in a tropical population; clinical course, cause and early predictors of outcome. Hepatology 1996; 23:1448-1455.
5. Yanagi M, Kaneko S, Unoura M, Morakami S, Kobayshi K, Sugihara J, et al. Hepatitis C virus in fulminant hepatic failure. N Engl J Med 1991; 324:1895-1896.
6. Feray C, Gigou M, Samuel D, Reyes G, Bernuau J, Reynes M, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993; 104:549-555.
7. Halasz R, Barkholt L, Lara C, Hultgren C, Ando Y, Broome U, et al. Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products. Gut 1999; 44:274-278.
8. Schoidt F, Atillasoy E, Shakil AO, Schiff E, Caldwell C, Kowdley K, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999; 5:29-34.
9. Fagan E. Reducing paracetamol overdoses. BMJ 1996; 313:1417-1418.
10. Schiodt F, Rochling F, Casey D, Lee W. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997; 337:1112-1117.
11. Whitcomb D, Block G. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 272:1845-1850.
12. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22:767-773.
13. Makin A, Wendon J, Williams R. A seven year experience of severe acetaminophen induced hepatotoxicity (1987-1993). Gastroenterology 1995; 109:1907-1916.
14. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319:1557-1562.
15. Harrison P, Keays R, Bray G, Alexander G, Williams R. Improved outcome of paracetamol induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990; 355:1572-1573.
16. Keays R, Harrison P, Wendon J, Forbes A, Gove C, Alexander G, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991; 303:1026-1029.
17. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53:536-548.
18. O'Grady J, Alexander G, Hayllar K, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439-445. First easily applicable selection criteria for liver transplantation in ALF.
19. Bihari D, Gimson A, Waterson M, Williams R. Tissue hypoxia during fulminant hepatic failure. Crit Care Med 1985; 13:1034-1039.
20. Bihari D, Gimson A, Williams R. Cardiovascular, pulmonary and renal complications of fulminant hepatic failure. Semin Liver Dis 1986; 6:119-128.
21. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solution in critically ill patients: a systematic review of randomised trials. BMJ 1998; 316:961-964.
22. Cochrane Injuries Reviewers Group. Human albumin administration in critically ill patients; a systematic review of randomised controlled trials. BMJ 1998; 317:235-240.
23. Shippy B, Appel P, Shoemaker W. Reliability of clinical monitoring to assess blood volume in critically ill patients. Crit Care Med 1984; 12:107-112.
24. Harrison P, Wendon J, Gimson A, Alexander G, Williams R. Improvement by acetylcysteine of haemodynamics and oxygen transport in fulminant hepatic failure. W Engl J Med 1991; 324:1852-1857.
25. Connors A, Speroff T, Dawson N, Thomas C, Harrell F, Wagner D, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996; 276:889-897.
26. Third European Consensus Conference in Intensive Care Medicine. Tissue hypoxia: how to detect, how to correct, how to prevent? Am J Resp Crit Care Med 1996; 154:1573-1578.
27. Olsen D, Pohlman A, Hall J. Administration of low dose dopamine to non oliguric patients with sepsis syndrome does not raise intramucosal pHi nor improve creatinine clearance. Crit Care Med 1996; 154:1664-1670.
28. Rolando N, Philpott HJ, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis 1996; 16:389-402. Concise summary of the problems of sepsis in ALF.
29. Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Gimson A, et al. Prospective study of bacterial infection in acute liver failure; an analysis of fifty patients. Hepatology 1990; 11:50-53.
30. Rolando N, Harvey F, Brahm J, Philpott HJ, Alexander G, Casewell M, et al. Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol 1991; 12:1-9.
31. Rolando N, Gimson A, Wade J, Philpott-Howard J, Casewell M, Williams R. Prospective trial of selective parenteral and enteral antimicrobiological regimen in fulminant liver failure. Hepatology 1993; 17:196-201.
32. Rolando N, Wade J, Stangou A, Gimson A, Wendon J, Philpot-Howard J, et al. Prospective study comparing prophylactic parenteral antimicrobials, with or without enteral decontamination in patients with acute liver failure. Liver Transpl Surg 1996; 2:8-13.
33. Blei A. Brain edema - its relationship to hepatic encephalopathy. In: Advances in Hepatic Encephalopathy and Metabolism in Liver Disease. Record C, Al-Mardini H (eds). Newcastle upon Tyne: University of Newcastle upon Tyne; 1997. pp. 259-267.
34. Yang SS, Hughes RD, Williams R. Digoxin-like immunoreactive substances in severe acute liver disease due to viral hepatitis and paracetamol overdose. Hepatology 1988; 8:93-97.
35. Ede R, Gimson A, Bihari D, Williams R. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 1986; 2:43-51.
36. Wendon J, Harrison P, Keays R, Williams R. Cerebral blood flow and metabolism in fulminant hepatic failure. Hepatology 1994; 19:1407-1413.
37. Larson F, Ejlerson E, Hanson B, Knudson G, Tygstrup N, Secher N. Functional loss of cerebral blood flow autoregulation in patients with fulminant hepatic failure. J Hepatol 1995; 23:212-217.
38. Davenport A, Will EJ, Davison AM. Effect of posture on intracranial pressure and cerebral perfusion pressure in patients with fulminant hepatic and renal failure after acetaminophen self-poisoning. Crit Care Med 1990; 18:286-289.
39. Keays R, Alexander G, Williams R. The safety and value of extradural intracranial pressure monitoring in fulminant hepatic failure. J Hepatol 1993; 18:205-209.
40. Blei A, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 1993; 341:157-158.
41. Davies M, Mutimer D, Lowes J, Elias E, Neuberger J. Recovery despite impaired cerebral perfusion in fulminant hepatic failure. Lancet 1994; 343:1329-1330.
42. Canalese J, Gimson A, Davis C, Melton P, Davis M, Williams R. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 1982; 23:625-629.
43. Forbes A, Alexander G, O'Grady J. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure. Hepatology 1989; 10:549-555.
44. O'Grady JG, Gimson AE, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94:1186-1192.
45. Davenport A, Will EJ, Davison AM, Swindells S, Cohen AT, Miloszewski KJ, et al. Changes in intracranial pressure during haemofiltration in oliguric patients with grade IV hepatic encephalopathy. Nephron 1989; 53:142-146.
46. Gimson A, Braude S, Mellon P, Canalese J, Williams R. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 1982; il:681-683.
47. Tygstrup N, Larson F, Hanson B. Treatment of acute liver failure by high volume plasmapheresis. In: Acute Liver Failure. Lee W, Williams R (eds). Cambridge: Cambridge University Press; 1997. pp. 267-277.
48. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24:1446-1451.
49. Arkadopoulos N, Detry O, Rozga J, Cemetriou A. Liver assist devices: state of the art. Int J Artif Organs 1998; 21:781-787. References [47-49] summarize recent experiences with therapies of likely future importance.
50. Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria. J Hepatol 1997; 26:62-68.
51. Bismuth H, Samuel D, Castaing D, Adam R, Saliba F, Johan M, et al. Orthoptic liver transplantation in fulminant and sub-fulminant hepatitis. The Paul Brousse experience. Ann Surg 1995; 222:109-119.
52. Bismuth H, Samuel D, Castaing D, Williams R, Pereira S. Liver transplantation in Europe for patients with acute liver failure. Semin Liver Dis 1996; 16:415-425.
53. Pereira LM, Langley PG, Hayllar KM, Tredger JM, Williams R. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators. Gut 1992; 33:98-102.
54. Itai Y, Sekiyama K, Ahmadi T, Obuchi M, Yoshiba M. Fulminant hepatic failure: observation with serial CT. Radiology 1997; 202:379-382.
55. Mitchell I, Bihari D, Chang R, Wendon J, Williams R. Earlier identification of patients at risk from acetaminophen induced acute liver failure. Crit Care Med 1998; 26:279-284.
56. Bernal W, Wendon J, Rela M, Heaton N, Williams R. Use and outcome of liver transplantation in acetaminophen induced acute liver failure. Hepatology 1998; 27:1050-1055.
57. Ascher N, Lake J, Edmond J, Roberts J. Liver transplantation for fulminant hepatic failure. Arch Surg 1995; 128:677-682.
58. Devlin J, Wendon J, Heaton N, Tan K, Williams R. Pretransplant clinical status and outcome of emergency transplantation for acute liver failure. Hepatology 1995; 21:1018-1024.